Questioning Four Preconceived Ideas on Immunotherapy of Clinical Type 1 Diabetes: Lessons from Recent CD3 Antibody Trials

SBDR - SOCIETY FOR BIOMEDICAL DIABETES RESEARCH
Questioning Four Preconceived Ideas on Immunotherapy of Clinical Type 1 Diabetes: Lessons from Recent CD3 Antibody Trials

Our Mission

Career Opportunities

Membership

Diabetes Open Directory

The Review of Diabetic Studies

SBDR>The Review of Diabetic Studies>Archive>2>3-Fall>Editorial> Lessons from Recent CD3 Antibody Trials

Lessons from Recent CD3 Antibody Trials

SciScript - Scientific article factory.
Professional proofreading by scientists and linguists.
Read more... klick here

http://www.sciscript.info/content/

Editorial

Rev Diabet Stud, 2005, 2(3):116-120

DOI 10.1900/RDS.2005.2.116

Questioning Four Preconceived Ideas on Immunotherapy of Clinical Type 1 Diabetes: Lessons from Recent CD3 Antibody Trials

Lucienne Chatenoud, Jean-François Bach

Université René Descartes Paris 5, INSERM U580, Hôpital Necker-Enfants Malades, Paris, France.
Address correspondence to: Jean-François Bach, e-mail: bach@necker.fr.

Abstract

n/a

Fulltext: HTML , PDF (312KB)

This article has been cited by other articles:

	"Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances? Sia C, Weinem M Rev Diabet Stud 2006. 3(4):156-160

	Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach Bresson D, von Herrath M Rev Diabet Stud 2005. 2(4):187-189

Internal Link

Questioning Four Preconceived Ideas on Immunotherapy of Clinical Type 1 Diabetes: Lessons from Recent CD3 Antibody Trials (312KB)